Form 4: Pfizer Director James C. Smith Acquires Phantom Stock Units as Deferred Compensation

Director James C. Smith reports acquisition of phantom stock units representing deferred compensation from Pfizer.

Summary

• On March 31, 2025, James C. Smith, a director of Pfizer Inc., acquired 1,775.848 phantom stock units as part of deferred director's compensation.
• These units, priced at $25.34 each, represent the right to receive cash or common stock upon retirement from the Board of Directors.
• Following the transaction, Smith directly owns 143,564.319 shares of Pfizer common stock.
• The filing also includes a power of attorney granted by James C. Smith to several individuals, authorizing them to file Section 16 forms on his behalf.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, indicating a stable and ongoing relationship between the director and the company. The use of deferred compensation suggests a long-term commitment.

Positives

• The acquisition of phantom stock units aligns the director's interests with the long-term performance of the company.
• Deferred compensation plans can be tax-efficient for both the company and the executive.

Future Outlook

The phantom stock units will be settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors.

Industry Context

Form 4 filings are routine disclosures required by the SEC for corporate insiders, providing transparency into their transactions in the company's securities. This filing is typical for directors receiving deferred compensation.

Comparison to Industry Standards

• Deferred compensation arrangements, including phantom stock units, are common among large publicly traded companies like Pfizer to attract and retain key executives and directors.
• Companies such as Johnson & Johnson and Merck also utilize similar compensation structures for their board members.
• The specific terms and amounts of deferred compensation vary based on company size, industry, and individual performance.

Stakeholder Impact

• The transaction has a minimal direct impact on shareholders, employees, customers, suppliers, and creditors.
• It reinforces the alignment of director interests with shareholder value through equity-based compensation.

Key Dates

Keywords

Form 4, Pfizer, Director, James C. Smith, Phantom Stock Units, Deferred Compensation, Beneficial Ownership, Section 16